HIV Needs Assessment Survey Question Title * 1. What is your current perspective on the conflicting data regarding the association of abacavir with increased risk of cardiovascular disease? A. I believe the risk is probably real B. The FDA meta-analysis showing no association reassured me that there is probably no significant risk C. Given the conflicting data, I am still uncertain as to whether or not there is an association D. No knowledge of these data Question Title * 2. What is your current practice regarding NRTIs in initial antiretroviral therapy? A. I start everyone on tenofovir/emtricitabine unless they have renal disease B. I consider abacavir/lamivudine or tenofovir/emtricitabine for everyone C. I rule out abacavir/lamivudine for patients with any level of cardiovascular risk D. I rule out abacavir/lamivudine only for those patients with the highest levels of cardiovascular risk E. Unsure Question Title * 3. You have a patient with hypertension and elevated creatinine on abacavir/lamivudine plus raltegravir who is virologically suppressed and doing well. She presents today a non-ST elevation myocardial infarction. How would you manage her antiretroviral therapy? A. Stay with current regimen B. Change abacavir to tenofovir C. Change abacavir to an NRTI other than tenofovir D. Switch to an NRTI-sparing regimen E. Unsure Question Title * 4. Which of the following statements reflects your use of boosted PI-based regimens as first-line therapy for patients with cardiovascular risk factors? A. I avoid the use of boosted PIs for these patients B. I choose darunavir/ritonavir more often than atazanavir/ritonavir C. I choose atazanavir/ritonavir more often than darunavir/ritonavir D. I use them equally E. Unsure Question Title * 5. What is your understanding of the results of ACTG 5257, the comparison of raltegravir, darunavir/ritonavir, and atazanavir/ritonavir, each combined with tenofovir/emtricitabine in first-line antiretroviral therapy? (Check all that apply) A. Raltegravir was superior to the PIs in all parameters B. The PIs were similar and superior to raltegravir in all parameters C. The 3 regimens were similar in efficacy but differed in tolerability D. Atazanavir/ritonavir was better than darunavir/ritonavir in the combined endpoint of efficacy and tolerability E. Darunavir/ritonavir was better than atazanavir/ritonavir in the combined endpoint of efficacy and tolerability F. Unsure G. I am unaware of these data Question Title * 6. How has your use of darunavir/ritonavir and atazanavir/ritonavir regimens changed during the past year since the release of the primary endpoint data from ACTG 5257? A. I use them both about the same as I used to B. I have increased my use of darunavir/ritonavir vs atazanavir/ritonavir C. I have increased my use of atazanavir/ritonavir vs darunavir/ritonavir D. I use them both less than I used to E. Unsure Question Title * 7. What is your understanding of the results of the cardiovascular substudy of ACTG 5257 (ACTG 5260s)? (Check all that apply) A. Raltegravir was superior to each of the PIs in all measures of cardiovascular risk B. The PIs were similar and superior to raltegravir in all parameters of cardiovascular risk C. Patients on atazanavir/ritonavir had slower progression carotid intima-media thickness than those on darunavir/ritonavir or raltegravir D. Patients on darunavir/ritonavir had slower progression carotid intima-media thickness than those on atazanavir/ritonavir or raltegravir E. Unsure F. I am unaware of these data Question Title * 8. How will the data from ACTG 5260s change your use of darunavir/ritonavir and atazanavir/ritonavir regimens? A. I will use them both about the same as I used to B. I will increase my use of darunavir/ritonavir vs atazanavir/ritonavir C. I will increase my use of atazanavir/ritonavir vs darunavir/ritonavir D. I use them both less than I used to E. Unsure F. I am unaware of these data Question Title * 9. What is included in your routine assessment of cardiovascular risk among your HIV patients? (Check all that apply) A. Serum lipids B. Measures of inflammatory markers C. Imaging methods D. Unsure Question Title * 10. How familiar are you with ultrasonic methods to assess cardiovascular risk? A. Very familiar; we have these methods in my clinic/hospital B. I am familiar with data about these methods but do not have direct access to them C. I am unfamiliar with these methods D. Unsure Question Title * 11. What is your specialty? A. Physician (Infectious Disease) B. Physician (HIV Specialist) C. Physician (Other) D. Pharmacist E. Registered Nurse F. Other Other (please specify) Question Title * 12. How many years have you been in practice? A. 0-5 B. 6-10 C. 11-15 D. >15 Question Title * 13. What is your practice setting? A. Solo B. Group C. Academic D. Other Other (please specify) Next